Boying Dun1, Ashok Sharma2, Heng Xu3, Haitao Liu2, Shan Bai2, Lingwen Zeng4, Jin-Xiong She3. 1. Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing University of Technology Nanjing, China ; Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University Augusta, GA, USA ; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences Guangzhou, China. 2. Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University Augusta, GA, USA. 3. Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing University of Technology Nanjing, China ; Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University Augusta, GA, USA. 4. Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences Guangzhou, China.
Abstract
BACKGROUND: Inhibition of inosine monophosphate dehydrogenase (IMPDH) by mycophenolic acid (MPA) can inhibit proliferation and induce apoptosis in cancer cells. This study investigated the underlying molecular mechanisms of MPA's anticancer activity. METHODS: A gastric cancer cell line (AGS) was treated with MPA and gene expression at different time points was analyzed using Illumina whole genome microarrays and selected genes were confirmed by real-time RT-PCR. RESULTS: Transcriptomic profiling identified 1070 genes with ≥2 fold changes and 85 genes with >4 fold alterations. The most significantly altered biological processes by MPA treatment include cell cycle, apoptosis, cell proliferation and migration. MPA treatment altered at least ten KEGG pathways, of which eight (p53 signaling, cell cycle, pathways in cancer, PPAR signaling, bladder cancer, protein processing in ER, small cell lung cancer and MAPK signaling) are cancer-related. Among the earliest cellular events induced by MPA is cell cycle arrest which may be caused by six molecular pathways: 1) up-regulation of cyclins (CCND1 and CCNE2) and down-regulation of CCNA2 and CCNB1, 2) down-regulation of cyclin-dependent kinases (CDK4 and CDK5); 3) inhibition of cell division related genes (CDC20, CDC25B and CDC25C) and other cell cycle related genes (MCM2, CENPE and PSRC1), 4) activation of p53, which activates the cyclin-dependent kinase inhibitors (CDKN1A), 5) impaired spindle checkpoint function and chromosome segregation (BUB1, BUB1B, BOP1, AURKA, AURKB, and FOXM1); and 6) reduction of availability of deoxyribonucleotides and therefore DNA synthesis through down-regulation of the RRM1 enzyme. Cell cycle arrest is followed by inhibition of cell proliferation, which is mainly attributable to the inhibition of the PI3K/AKT/mTOR pathway, and caspase-dependent apoptosis due to up-regulation of the p53 and FAS pathways. CONCLUSIONS: These results suggest that MPA has beneficial anticancer activity through diverse molecular pathways and biological processes.
BACKGROUND: Inhibition of inosine monophosphate dehydrogenase (IMPDH) by mycophenolic acid (MPA) can inhibit proliferation and induce apoptosis in cancer cells. This study investigated the underlying molecular mechanisms of MPA's anticancer activity. METHODS: A gastric cancer cell line (AGS) was treated with MPA and gene expression at different time points was analyzed using Illumina whole genome microarrays and selected genes were confirmed by real-time RT-PCR. RESULTS: Transcriptomic profiling identified 1070 genes with ≥2 fold changes and 85 genes with >4 fold alterations. The most significantly altered biological processes by MPA treatment include cell cycle, apoptosis, cell proliferation and migration. MPA treatment altered at least ten KEGG pathways, of which eight (p53 signaling, cell cycle, pathways in cancer, PPAR signaling, bladder cancer, protein processing in ER, small cell lung cancer and MAPK signaling) are cancer-related. Among the earliest cellular events induced by MPA is cell cycle arrest which may be caused by six molecular pathways: 1) up-regulation of cyclins (CCND1 and CCNE2) and down-regulation of CCNA2 and CCNB1, 2) down-regulation of cyclin-dependent kinases (CDK4 and CDK5); 3) inhibition of cell division related genes (CDC20, CDC25B and CDC25C) and other cell cycle related genes (MCM2, CENPE and PSRC1), 4) activation of p53, which activates the cyclin-dependent kinase inhibitors (CDKN1A), 5) impaired spindle checkpoint function and chromosome segregation (BUB1, BUB1B, BOP1, AURKA, AURKB, and FOXM1); and 6) reduction of availability of deoxyribonucleotides and therefore DNA synthesis through down-regulation of the RRM1 enzyme. Cell cycle arrest is followed by inhibition of cell proliferation, which is mainly attributable to the inhibition of the PI3K/AKT/mTOR pathway, and caspase-dependent apoptosis due to up-regulation of the p53 and FAS pathways. CONCLUSIONS: These results suggest that MPA has beneficial anticancer activity through diverse molecular pathways and biological processes.
Entities:
Keywords:
MPA; drug repurposing; microarray; regulatory networks
Authors: Paul Shannon; Andrew Markiel; Owen Ozier; Nitin S Baliga; Jonathan T Wang; Daniel Ramage; Nada Amin; Benno Schwikowski; Trey Ideker Journal: Genome Res Date: 2003-11 Impact factor: 9.043
Authors: Jamila Laoukili; Matthijs R H Kooistra; Alexandra Brás; Jos Kauw; Ron M Kerkhoven; Ashby Morrison; Hans Clevers; René H Medema Journal: Nat Cell Biol Date: 2005-01-16 Impact factor: 28.824
Authors: Yu Zeng; Yanan He; Fan Yang; Steven M Mooney; Robert H Getzenberg; John Orban; Prakash Kulkarni Journal: J Biol Chem Date: 2011-02-25 Impact factor: 5.157
Authors: S L Silva; S F R Silva; R O Cavalcante; R S Mota; R A Carvalho; M O Moraes; H H Campos; M E A Moraes Journal: Transplant Proc Date: 2004-05 Impact factor: 1.066
Authors: Raúl González; Gustavo Ferrín; Patricia Aguilar-Melero; Isidora Ranchal; Clara I Linares; Rosario I Bello; Manuel De la Mata; Vladimir Gogvadze; José A Bárcena; José M Alamo; Sten Orrenius; Francisco J Padillo; Boris Zhivotovsky; Jordi Muntané Journal: Antioxid Redox Signal Date: 2012-09-26 Impact factor: 8.401
Authors: Ravi K Chilukoti; Josefine Lendeckel; Katrin Darm; Alicja Bukowska; Andreas Goette; Marc Sühling; Kirsten Utpatel; Barbara Peters; Georg Homuth; Uwe Völker; Carmen Wolke; Christian Scharf; Uwe Lendeckel Journal: Exp Biol Med (Maywood) Date: 2018-07
Authors: Qing Wen; Paul O'Reilly; Philip D Dunne; Mark Lawler; Sandra Van Schaeybroeck; Manuel Salto-Tellez; Peter Hamilton; Shu-Dong Zhang Journal: BMC Syst Biol Date: 2015-09-01